Cargando…

PB2362: THE EFFECT OF BODY MASS INDEX (BMI) ON THE PROGNOSIS OF DLBCL PATIENTS TREATED WITH R-CHOP: A REAL WORLD MOROCCAN EXPERIENCE

Detalles Bibliográficos
Autores principales:	el Filali, Imane Ait, Mahtat, El Mehdi, Nora, Elmaachi, Jennane, Selim, el Maaroufi, Hicham, Kamal, Doghmi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429232/ http://dx.doi.org/10.1097/01.HS9.0000976164.00280.8d

Ejemplares similares

PB2128: CELL OF ORIGIN ACCORDING TO HANS LOGARITHM IS AN INDEPENDENT RISK FACTOR FOR DLBCL PATIENTS TREATED WITH R-CHOP: A REAL WORLD MOROCCAN EXPERIENCE
por: Mahtat, E. M., et al.
Publicado: (2022)

PB1996: CYTOGENETIC FEATURES OF 164 MOROCCAN PATIENTS WITH MYELODYSPLASTIC SYNDROME
por: Aghoutane, Yossra, et al.
Publicado: (2023)

PB2693: ANEMIA IN HEMATOLOGIC MALIGNANCIES: NOT ONLY A SYMPTOM.
por: Hari, Oumayma, et al.
Publicado: (2023)

PB1784: CYTOGENETIC LANDSCAPE OF 87 MOROCCAN ACUTE MYELOID LEUKEMIA PATIENTS
por: Mahtat, E. M., et al.
Publicado: (2022)

L’érythroblastopénie et la myélofibrose primitive: association très rare (à propos d’un cas)
por: EL Maachi, Nora, et al.
Publicado: (2022)

PB1839: CYTOGENETIC PROFILE OF ACUTE MYELOBLASTIC LEUKEMIA TREATED AT THE MOHAMMED V MILITARY HOSPITAL IN RABAT (MOROCCO).
por: Hawa, Moussa Bouh, et al.
Publicado: (2023)

Posterior Reversible Encephalopathy Syndrome Secondary to R-CHOP Chemotherapy Regimen
por: Jennane, Selim, et al.
Publicado: (2022)

PB2081: CYTOGENETICS OF MULTIPLE MYELOMA IN MOROCCO
por: Moutmir, Yasmine, et al.
Publicado: (2023)

Erdheim-Chester disease: a rare histiocytosis (case report and review of the literature)
por: Mehdi, Mahtat El, et al.
Publicado: (2018)

Bleomycin-Induced Lung Toxicity in Hodgkin's Lymphoma: Risk Factors in the Positron Emission Tomography Era
por: Jennane, Selim, et al.
Publicado: (2022)

P1074: PRIMARY REFRACTORY HODGKIN’S LYMPHOMA: A MOROCCAN MONOCENTRIC RETROSPECTIVE STUDY
por: Ababou, M., et al.
Publicado: (2022)

Acute Laryngeal Dyspnea as the First Presentation of Mantle Cell Lymphoma: A Case Report and Review of the Literature
por: Ababou, Mounir, et al.
Publicado: (2020)

Une polyradiculonévrite inflammatoire démyélinisante chronique paranéoplasique secondaire à un lymphome natural killer nasal
por: Jennane, Selim, et al.
Publicado: (2020)

PB2131: CLINICAL CHARACTERISTICS AND TREATMENTS OUTCOMES OF PRIMARY GASTROINTESTINAL LYMPHOMA:RETROSPECTIVE SINGLE CENTER STUDY FROM MOROCCO
por: Nora, E., et al.
Publicado: (2022)

PB2325: VALIDATION OF THE TRAIL SCORE TO PREDICT TOXICITY IN PATIENTS WITH DLBCL RECEIVING R-CHOP-LIKE THERAPY
por: Caballero, Juan Carlos, et al.
Publicado: (2023)

PB2134: THE ROLE OF ADDITIONAL CARBOGEN GAS MIXTURE AND NICOTINAMIDE ON R-CHOP CHEMOTHERAPY IN DLBCL PATIENTS WITH TUMOR HYPOXIA
por: Rizky, D., et al.
Publicado: (2022)

PB2362: BEST PRACTICES ON EMPOWERING AND INVOLVING PATIENTS LIVING WITH HEMATOLOGICAL MALIGNANCIES ON THE DEVELOPMENT OF NOVEL PATIENT-REPORTED OUTCOME MEASURES
por: Vrontaras, N., et al.
Publicado: (2022)

PB2301: OPTIMAL DOSE INTENSITY OF R-CHOP FOR PATIENTS WITH DLBCL AGED 80 YEARS OR OLDER: IS THE R-MINICHOP A GOLD STANDARD?
por: Nukariya, Hironao, et al.
Publicado: (2023)

PB2170: HIGH EXPRESSION OF AP2M1 CORRELATES WITH WORSE PROGNOSIS BY REGULATING IMMUNE MICROENVIRONMENT AND DRUG RESPONSE TO R-CHOP IN DLBCL
por: Liu, X.-D., et al.
Publicado: (2022)

Prise en charge des syndromes myélodysplasiques au Maroc à propos d´une étude mono-centrique
por: Maaroufi, Hicham El, et al.
Publicado: (2020)

Glomérulonéphrite extra-membraneuse et syndrome myélodysplasique: une association rare
por: Mehdi, Mahtat El, et al.
Publicado: (2018)

PB2379: SPECIFIC ALTERATIONS IN MEMBRANE LIPID LEVELS AS POTENTIAL BIOMARKERS IN DLBCL PATIENTS
por: Loscocco, Federica, et al.
Publicado: (2023)

PB2370: EXTRANODAL NATURAL KILLER (NK)/T-CELL LYMPHOMA, NASAL-TYPE: ABOUT 11 CASES
por: Aghoutane, Yossra, et al.
Publicado: (2023)

PB2335: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHOP (O-CHOP) VERSUS R-CHOP IN PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (OLYMPIA-3)
por: Tessoulin, Benoit, et al.
Publicado: (2023)

PB2152: BIOLOGICAL AND CLINICAL CORRELATES OF GALECTIN-3 (GAL-3) EXPRESSION IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
por: Basic-Kinda, S., et al.
Publicado: (2022)

PB2145: REAL-WORLD THERAPY LINES IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) – A POPULATION-BASED ANALYSIS
por: Duell, J., et al.
Publicado: (2022)

PB2127: NO IMPACT OF STATIN USE ON RESPONSE AND SURVIVAL RATES IN NEWLY DIAGNOSED DLBCL PATIENTS TREATED WITH R-DA-EPOCH
por: Sabljic, A., et al.
Publicado: (2022)

PB2126: R-CPOP AS FIRST LINE TREATMENT FOR DLBCL PATIENTS WITH SIGNIFICANT REDUCED LVEF OR HIGH RISK OF ANTHRACYCLINE INDUCED CARDIOTOXICITY
por: Lorenz, K., et al.
Publicado: (2022)

PB2105: REAL WORLD EXPERIENCE WITH POLATUZUMAB IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB FOR R/R DLBCL IN 3 ACADEMIC CENTERS IN MADRID, SPAIN.
por: Corrochano, M., et al.
Publicado: (2022)

PB2293: REAL WORLD STUDY OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IN THE ELDERLY: FOURTEEN YEARS OF ONE CENTER’S EXPERIENCE
por: De Ascanio, Victoria Ramos, et al.
Publicado: (2023)

PB2376: ASSAY DEVELOPMENT AND VALIDATION OF IG-HTS TO MONITOR MRD IN PLASMA OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
por: Wu, Jinghua, et al.
Publicado: (2023)

PB2363: R-MPV FOLLOWED BY CONSOLIDATION REDUCED-DOSE WHOLE-BRAIN RADIOTHERAPY AND CYTARABINE IN NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA: REAL WORLD DATA
por: Amani, Maha EL, et al.
Publicado: (2023)

PB2308: NIVOLUMAB-BASED THERAPY OF RELAPSED OR REFRACTORY PRIMARY LARGE B-CELL LYMPHOMA OF IMMUNE-PRIVILEGED SITES AND DLBCL WITH SECONDARY CNS INVOLVEMENT
por: Gavrilenko, Andrey, et al.
Publicado: (2023)

PB2667: AUTOIMMUNE DISEASES REVEALED BY SPLANCHNIC THROMBOSIS
por: Laabichi, Amine, et al.
Publicado: (2023)

PB2119: LONG-TERM SURVIVAL PROJECTIONS OF LONCASTUXIMAB TESIRINE-TREATED PATIENTS IN RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
por: Hamadani, M., et al.
Publicado: (2022)

PB2118: PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH RITUXIMAB (LONCA-R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH R/R DLBCL (LOTIS-5)
por: Hamadani, M., et al.
Publicado: (2022)

PB1942: HEPATIC MANIFESTATIONS OF CHILDHOOD HEMOPHAGOCYTIC LYMPHOHISTOCYTOSIS
por: El Sayed, M., et al.
Publicado: (2022)

PB2253: NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) AS A PREDICTOR OF SEVERE COVID-19 ON ADMISSION
por: Ababou, M., et al.
Publicado: (2022)

PB2113: FRONTMIND: A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TAFASITAMAB + LENALIDOMIDE + R-CHOP VS R-CHOP ALONE FOR NEWLY DIAGNOSED HIGH-INTERMEDIATE AND HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA
por: Vitolo, U., et al.
Publicado: (2022)

PB2104: DOSE-DENSE CHEMOTHERAPY WITH R-CHOP-14 IN OLDER ADULTS AGED ≥80 YEARS WITH DIFFUSE LARGE B-CELL LYMPHOMA
por: Christofyllakis, K., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_phad9p60iie0m60tdhiq28bfmn